For those obese patients, doctors may need to prescribe medicines
Efficacy and safety of coadministered onceweekly cagrilintide 2.4 mg with onceweekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, doubleblind, activecontrolled, phase 2 trial
We may not be aware of patents that have already been issued and that a third party, for example, a competitor in the fields in which we are developing our product candidates, might assert are infringed by our product candidates, including claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our product candidates
doi: 10.1016/j.neurobiolaging.2019.10.014 27 JarrellZ
That will help expand coverage, according to Dave Moore, Novo's executive vice president for U.S